✦ LIBER ✦

RELATION BETWEEN 131I THERAPY FOR THYROTOXICOSIS AND DEVELOPMENT OF THYROID CARCINOMA

✍ Scribed by Williams, E.D.

Book ID: 122964956
Publisher: The Lancet
Year: 1986
Tongue: English
Weight: 328 KB
Volume: 328
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(86)92159-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioiodide (131)I therapy for the treat

Radioiodide (131)I therapy for the treatment of canine thyroid carcinoma

✍ AJ WORTH; RM ZUBER; M HOCKING 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB

RELATION OF ENDEMIC GOITER TO THYROID CA

RELATION OF ENDEMIC GOITER TO THYROID CARCINOMA AND THYROTOXICOSIS

📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

Relation between clinical and laboratory

Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma

✍ Asli, I. N.; Baharfard, N.; Shafiei, B.; Tabei, F.; Javadi, H.; Seyedabadi, M.; 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 99 KB

Localized well-differentiated thyroid ca

Localized well-differentiated thyroid carcinoma: Survival analysis of prognostic factors and131I therapy

✍ Don M. Morris; Patrick J. Boyle; Christine A. Stidley; Kathleen K. Altobelli; Te 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 904 KB

131I gastric uptake with and without ome

131I gastric uptake with and without omeprazole in patients undergoing radioiodine therapy for differentiated thyroid carcinoma

✍ Castro, Gabriel; Berrocal, Isabel; Carmona, Jaime; González, Javiera; González, 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 80 KB

Thyroid Cancer Volume 779 || Side Effect

Thyroid Cancer Volume 779 || Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma

✍ Wartofsky, Leonard; Nostrand, Douglas 📂 Article 📅 2006 🏛 Humana Press 🌐 English ⚖ 489 KB

This Book Will Help The Reader To Understand Fully The Role Of Nuclear Medicine In Managing Thyroid Cancer Patient; Follow The Latest Evidence-based Recommendations And Guidelines Wherever Possible; Assess The Promising Uses Of Recombinant Human Thyrotropin; Refer Patients To Phase 1-3 Clinical Tria